Fannin
Houston-based early-stage life-sciences development studio (est. 2014) that in-licenses, develops, and incubates therapeutic and medical device assets. Operates a studio team that de-risks technologies with grant and investor funding, spins programs into standalone companies, and provides investor co-investment opportunities and training programs for early-career scientists.
Industries
N/A
Nr. of Employees
small (1-50)
Fannin
3900 Essex Lane, Suite 575, Houston, Texas 77027
Patents
Products
Procyrion (Aortix percutaneous circulatory support device)
Portfolio medical-device company developing a percutaneous mechanical circulatory support device; referenced pivotal IDE and clinical trials.
Pulmotect (inhaled immune-stimulatory therapeutic)
Clinical-stage inhaled therapeutic intended to stimulate innate immunity to prevent pulmonary infection; referenced Phase 2 trials.
Brevitest (CLIA laboratory and rapid testing platform)
CLIA-certified clinical laboratory leveraging automation and cloud computing to deliver rapid laboratory-quality results.
Allterum Therapeutics (therapeutic antibody programs)
Biopharmaceutical portfolio company developing monoclonal antibody therapeutics for oncology indications, including programs that have received grant funding and regulatory milestones.
Procyrion (Aortix percutaneous circulatory support device)
Portfolio medical-device company developing a percutaneous mechanical circulatory support device; referenced pivotal IDE and clinical trials.
Pulmotect (inhaled immune-stimulatory therapeutic)
Clinical-stage inhaled therapeutic intended to stimulate innate immunity to prevent pulmonary infection; referenced Phase 2 trials.
Brevitest (CLIA laboratory and rapid testing platform)
CLIA-certified clinical laboratory leveraging automation and cloud computing to deliver rapid laboratory-quality results.
Allterum Therapeutics (therapeutic antibody programs)
Biopharmaceutical portfolio company developing monoclonal antibody therapeutics for oncology indications, including programs that have received grant funding and regulatory milestones.
Services
End-to-end de-risking and program management for early therapeutic and device assets, including preclinical strategy, operational execution and spin-out formation.
Structuring in-licenses and forming new companies to advance assets beyond studio-stage development.
Preparation and submission of grant proposals and administration of grant-funded development work.
Programmatic co-investment vehicle enabling accredited investors to co-invest in studio spin-outs with deal-level discretion and no ongoing management fees.
Regulatory planning and operational support for IND/IDE-enabling activities, early-phase trial initiation and regulatory submissions.
Structured experiential training programs providing hands-on experience in therapeutics and medical-device commercialization, with didactic supplements.
End-to-end de-risking and program management for early therapeutic and device assets, including preclinical strategy, operational execution and spin-out formation.
Structuring in-licenses and forming new companies to advance assets beyond studio-stage development.
Preparation and submission of grant proposals and administration of grant-funded development work.
Programmatic co-investment vehicle enabling accredited investors to co-invest in studio spin-outs with deal-level discretion and no ongoing management fees.
Regulatory planning and operational support for IND/IDE-enabling activities, early-phase trial initiation and regulatory submissions.
Structured experiential training programs providing hands-on experience in therapeutics and medical-device commercialization, with didactic supplements.
Expertise Areas
- Early-stage product development and de-risking
- Clinical trial management and clinical operations
- Biologics and therapeutic antibody development
- Medical device development and commercialization
Key Technologies
- Monoclonal antibody therapeutics
- Aptamer-based discovery platforms
- Radiopharmaceutical targeting vectors
- Percutaneous mechanical circulatory support devices
News & Updates
Studio-hosted investor event scheduled for September 12, 2025 in Houston, TX.
Description of a co-investment vehicle offering access to studio deal flow and programmatic investing with no ongoing management fee for co-investors.
Studio references more than $242 million raised via grants and investor funding to advance programs.
Studio reports having trained over 300 interns and fellows through internship and associate programs.
Portfolio companies have reached regulatory and funding milestones (e.g., IND clearance, FDA Fast Track designation, Phase 2 trial initiations, manufacturing collaborations).
Studio-hosted investor event scheduled for September 12, 2025 in Houston, TX.
Description of a co-investment vehicle offering access to studio deal flow and programmatic investing with no ongoing management fee for co-investors.
Studio references more than $242 million raised via grants and investor funding to advance programs.
Studio reports having trained over 300 interns and fellows through internship and associate programs.
Portfolio companies have reached regulatory and funding milestones (e.g., IND clearance, FDA Fast Track designation, Phase 2 trial initiations, manufacturing collaborations).